Takeda Pharmaceutical Files July 2024 6-K Report

Ticker: TKPHF · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1395064

Takeda Pharmaceutical Co Ltd 6-K Filing Summary
FieldDetail
CompanyTakeda Pharmaceutical Co Ltd (TKPHF)
Form Type6-K
Filed DateJul 1, 2024
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: sec-filing, foreign-private-issuer, regulatory-update

TL;DR

Takeda filed its July 6-K, confirming 20-F annual report status. Standard update.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on July 1, 2024, reporting information for the month of July 2024. The filing indicates Takeda is a foreign private issuer and will file its annual reports under Form 20-F. The company's principal executive offices are located in Tokyo, Japan.

Why It Matters

This filing serves as an update for investors regarding Takeda's regulatory reporting status as a foreign private issuer. It confirms their adherence to SEC filing requirements.

Risk Assessment

Risk Level: low — This is a routine filing confirming reporting status and providing basic company information, with no new material financial or operational data.

Key Players & Entities

  • TAKEDA PHARMACEUTICAL CO LTD (company) — Filer
  • 0001395064-24-000102 (other) — Accession Number
  • 20240701 (date) — Filing Date
  • 001-38757 (other) — SEC File Number
  • Tokyo, Japan (location) — Principal Executive Offices

FAQ

What type of SEC filing is this?

This is a Form 6-K, a Report of Foreign Private Issuer.

Who is the filer of this report?

The filer is TAKEDA PHARMACEUTICAL CO LTD.

What is the filing date of this report?

The filing date is July 1, 2024.

Under which form will Takeda file its annual reports?

Takeda will file its annual reports under Form 20-F.

Where are Takeda's principal executive offices located?

Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.

Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 15 · Accepted 2024-07-01 06:33:23

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date July 1, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.